Scholars Central

Research articlePublished 1 Mar 2024

Use of a Kappa-carrageenan Nasal Solution in the Prophylaxis Treatment of Respiratory Infection Against Viruses Influenza (H1N1), Coronavirus (SARS-CoV-2) and Chronic Obstructive Pulmonary Diseases (COPD)

Authors: Padmanabha Reddy RV

Journal of Infectious Diseases & Preventive Medicine

Volume 12 · Issue 2 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: The nasal mucosa is the primary site of infection and replication for most cold-causing viruses including influenza (H1N1) and SARS-CoV-2. It was hypothesized, carrageenan’s would block viral entry at respiratory mucosa and interfere with viral replication propagation locally. The goal of this experiment was to test the antiviral effects of kappa carrageenan and Iota carrageenan in fully differentiated human airway epithelial cells cultivated at the airliquid interface against influenza (H1N1) and SARS-CoV-2 virus infection. Methods: To assess the efficacy of test product on human airway epithelial cells, apical viral replication (genome copy number) was quantified, tissue integrity was measured. Epithelia (MucilAir™-Pool) cells were used for the study. The experiment was designed to test the antiviral effects of kappa carrageenan in fully differentiated human airway epithelial cells cultivated at the air-liquid interface against influenza (H1N1) and SARS-CoV-2 infection. Results: Study results show the reference drug oseltamivir inhibits apical H1N1genome copies by >3 log10, Kappa carrageenan by >1 log10 units and Iota carrageenan by and Iota Carrageenan by 2 units. About SARS-CoV-2 infection study results indicate; SARS-CoV-2 apical replication at both time points, by 3.2; 2.3 log10 and 2.1 and 1.1 log10 respectively. Drug Remdesivir inhibits apical SARS-CoV-2 genome copies at 48 and 72 hours, by 3.4 and 4.2 log10, respectively. Kappa carrageenan and Iota carrageenan effectively inhibits SARS-CoV-2 apical replication at both time points, by 3.2, 2.3 log10 and 2.1 and 1.1 log10 respectively. Conclusion: The study demonstrates that antiviral effect developed Kappa Carrageenan nasal spray product has better efficacy than the Iota carrageenan comparator product.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Preventive Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Preventive Medicine
  • SubjectInfectious Diseases
  • SubjectPublic Health & Epidemiology
  • BylineArticles whose byline prints “Padmanabha Reddy RV”